What is the main purpose of this 8-K filing by Pfizer?

The main purpose of this 8-K filing is to officially report on Pfizer's proposed merger with Warner-Lambert Company and to incorporate by reference an advertisement that provides further details about this significant transaction.

Where can I find more information about the proposed merger with Warner-Lambert?

This filing directs investors to an advertisement published on December 15, 1999, in major news publications. Additionally, the filing suggests referring to other documents filed by Pfizer with the SEC, which identify important risk factors and provide further context.

What are the potential implications of the Warner-Lambert merger for Pfizer shareholders?

While this specific filing does not detail the implications, a merger of this magnitude typically aims to expand market share, enhance product portfolios, achieve cost synergies, and drive revenue growth. Investors should consult Pfizer's other SEC filings and the referenced advertisement for specific details and potential risks.

PFE 8-K SEC Disclosure — Dec 15, 1999

Summary

Pfizer Inc. (PFE) filed a Current Report (8-K) on December 15, 1999, primarily to announce and provide information regarding its proposed merger with Warner-Lambert Company. The filing incorporates by reference an advertisement published on the same date in major financial news outlets, including The New York Times and The Wall Street Journal. This advertisement likely details the strategic rationale, terms, and anticipated benefits of this significant transaction, which would represent a major step in Pfizer's corporate growth and market positioning.

Key Highlights

1Pfizer Inc. announced its proposed merger with Warner-Lambert Company.
2The filing incorporates an advertisement published on December 15, 1999, detailing the merger.
3The advertisement appeared in prominent publications like The New York Times and The Wall Street Journal.
4This 8-K filing serves to officially report on this significant corporate event.
5The merger represents a substantial strategic move for Pfizer.
6Investors are directed to other SEC filings for important risk factors associated with forward-looking statements.

PFIZER INC 8-K Report (Dec 15, 1999)

Summary

Key Highlights

Frequently Asked Questions